Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275825 | 0.92 | GRM5 (0.36) | GRM5MEN1KMT2APOLBMAPT | |
| SCHEMBL10313627 | 0.89 | GRM5 (0.36) | GRM5MEN1KMT2APOLBMAPT | |
| SCHEMBL10313623 | 0.87 | MEN1 (0.44) | MEN1KMT2APOLBMAPT | |
| SCHEMBL10313615 | 0.84 | KMT2A (0.32) | MEN1KMT2API4KAPI4K2BPI4K2A | |
| SCHEMBL10276120 | 0.78 | GLA (0.34) | GRM5POLBMAPT | |
| SCHEMBL10313621 | 0.76 | TYR (0.36) | POLBMAPT | |
| SCHEMBL10275724 | 0.75 | ADORA2A (0.39) | POLBMAPT | |
| SCHEMBL10275894 | 0.74 | PI4KA (0.36) | GRM5MEN1KMT2AMAPTPI4KA | |
| SCHEMBL10313618 | 0.74 | XDH (0.37) | GRM5MEN1KMT2APOLBMAPT | |
| SCHEMBL12826372 | 0.73 | ADORA2A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | GRM5 2021/4885MEN1 4229/4885KMT2A 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.